Single cells

Encapsulating Biology
Transforming Discovery

Our novel research and integrated instruments and collaborative research services enable the rapid engineering, screening and characterisation of single cells and their biological products. These cells are subsequently useful in research, biotherapeutics, bioproduction, cell therapy, drug discovery and diagnostics.

If you’re searching for rare and valuable variants within large cell populations, or wish to engineer them, we can help you do it faster, more cost-effectively and with a greater chance of success.

The Fast and Effective Engineering and Screening of Single Cells for Research and Development Applications

With flexible, future-proofed technologies we boost assay throughput and sensitivity, reduce consumable usage and optimise discovery, development and bioproduction across a broad range of applications.

Biopharmaceuticals and antibody production

Biopharmaceutical Discovery and Development

Increase the throughput and speed of your R&D pipeline. Better characterise biotherapeutic products. Carry out effective cell sorting and retrieval – and find those ‘rare’ variants.

Read More

Synthetic biology

Bioproduction and Synthetic Biology

Rapidly screen large libraries to sort through diverse populations of bacteria, yeast, hybridomas and transformed cells to find the best clones with the relevant phenotype.

Read More

Cell therapy engineering, analysis and isolation

Cell Therapy Engineering and Genome Editing

Use primary cells or precision engineer or transform, analyse and select cells for therapeutic applications, such as using engineered T-Cells for cell therapy, or novel research studies.

Read More

Drug discovery and biotherapeutics

Single Cell Disease Research

Carry out in-depth studies into infectious diseases, cancer and autoimmune disease through the effective compartmentalisation and analysis of single cells from disease-related samples.

Read More

Metagenomic analyses


Use our systems to carry out comprehensive metagenomic analyses that probe deeper into complex conditions, such as metabolic disorders and poorly defined diseases.

Read More

Single cell diagnostics

Single Cell Diagnostics and Prognostics

Our technology is an effective tool for purifying complex clinical samples and analysing single cells to improve patient diagnosis and better predict prognosis.

Read More

Lorem Ipsum Dolor Sit Amet

Lorem ipsum dolor sit amet, sit soluta aliquam at, minim virtute eu per. Nec ne duis reque iriure, et tota novum facilisi usu, principes constituam qui ea. Mel aperiri vocibus cu, no eos saperet prodesset. Quo populo disputando ut. Per suas complectitur no, vel in viris quando qualisque. Et wisi graeco habemus eam, in nulla assentior mnesarchum mel, ne his nominavi partiendo.

Soluta deterruisset nam ei, esse sanctus consulatu ad pro. Legere graece vis ne, has ut ludus facilisi. Ea eos principes assentior, mei nibh maiorum minimum ad. His id nibh dolore, pro percipitur consequuntur cu, eos consequat adipiscing id.


Our technology makes it possible to screen billions of cells and provides you with the best chance of finding that rare and valuable variant.

How do we do this? With microfluidic technology that allows the ultra-high throughput analysis of isolated single cells in miniaturised (pL to nL) volumes, picodroplets.

We offer a number of systems, from fully automated and integrated solutions designed for ‘plug and play’ use, through to flexible research instruments and customised research services for use in laboratories with more specialised needs. Our range of cost-effective consumables is specifically designed to work harmoniously with our instruments, providing significant time, cost and energy savings when used together.

Our technology and expertise is applied with our novel workflows to aid the discovery and development of therapeutics from single cells. Whether it’s for short research projects, technology development programs or partnerships, we provide a range of specialist collaborative services to suit your needs. Together we can reduce the cost and complexity of your research, and increase the speed of your discoveries.

Sphere Fluidics closes $2 million USD (c. £1.5 million GBP) investment round

  • Investment received from Greenwood Way Capital, Oxford Technology and Innovations EIS Fund and 24Haymarket
  • Funding will be used to accelerate growth in operations and sales across the UK and USA

Cambridge, UK, 29 January 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that is has closed a $2 million (circa £1.5 million) investment round. The Company secured funding from several investors including Greenwood Way Capital, Oxford Technology and Innovations EIS Fund and 24Haymarket. The funds raised will be used to accelerate growth in operations and support sales of its Cyto-Mine® Single Cell Analysis System.

Sphere Fluidics’ Cyto-Mine is an automated platform which integrates single cell screening, sorting, dispensing, imaging and clone verification. It can process up to 40 million cells per day, and assesses and isolates those that produce a specific biologic to help streamline workflows and improve throughput in antibody discovery and cell line development. The Company will use the investment to expand operations and sales capabilities across the UK and USA and open a new US West Coast Sales Office.

Frank F Craig PhD MBA, CEO, Sphere Fluidics, said: “We are pleased to see such a high level of interest in Sphere Fluidics and receive funding from several leading investors. We are making further investment in automating and streamlining our manufacturing processes across our product range to extend our offering and to deliver our high-quality standards and service to more researchers working in biotherapeutic discovery and cell line development across the UK and USA. We will be raising additional funds to expand these capabilities further.”

Cyto-Mine will be on display in Washington, DC at SLAS 2019 from 2nd to 6th February 2019 (Booth #1655 and #1429).

For more information about Sphere Fluidics and Cyto-Mine, please visit:



The Single Cell Analysis & Monoclonality Assurance System

Cyto-Mine® is the next generation platform that will transform
biopharmaceutical discovery and cell line development workflows.

For further information please contact:

 Sphere Fluidics

Dr Frank Craig, CEO

Tel: +44 (0)1223 804201


Greenwood Way Capital

Mr Ian Leigh BSc MBA


Oxford Technology & Innovations EIS Fund

Mr Freddie Hamilton BEnvs MPhil




 Zyme Communications

Dr Michelle Ricketts

Tel: +44 (0)7789 053885



Mr Paul Tselentis BA


About Sphere Fluidics

Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems for biotherapeutic discovery and cell line development.

Sphere Fluidics’ Cyto-Mine® System integrates selective screening of tens of millions of single cells, sorting, dispensing, imaging and clone verification into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value clones to be captured in a single run. Cyto-Mine® is underpinned by the Company’s patented microfluidic picodroplet technology.

Sphere Fluidics is located in Babraham, Cambridgeshire (UK) and Monmouth Junction, New Jersey (USA). The Company has also internationalized its business via a global network of distributors.

About Greenwood Way Capital

Greenwood Way Capital (GWC) offers their members, both funds and individuals, the opportunity to co-invest in early stage companies. The investment opportunities are usually selected by our partner syndicates and are usually early-stage UK companies which have innovative ideas or unique disruptive technologies and are led by highly entrepreneurial management. GWC members will invest in exactly the same class of shares and have the same rights as other shareholders. In early stage investing documentation is key. Our members will be signing the same subscription documentation and shareholder agreements that have been compiled by seasoned investors in the lead syndicate.

About Oxford Technology & Innovations EIS Fund

OTIF invests in spinout companies from world-leading universities in the UK, with a focus upon Oxford and Cambridge. The fund is structured to take advantage of HMRC’s Enterprise Investment Scheme (EIS), designed to help small companies less than ten years old raise finance by offering tax reliefs to individuals investing in these companies. Oxford Investment Consultants is investment adviser to Thompson Taraz Managers Ltd, the investment manager of OTIF. Oxford Investment Consultants (OIC) is a highly specialized investment advisory partnership that performs research analysis and offers advisory services on companies that are the product of UK university grant-funded scientific development in a broad array of fields. As of January 2019, OTIF has raised approximately £38.6m, with £33.7m of this invested in 32 companies.

About 24Haymarket

24Haymarket is a premium deal-by-deal investment platform focused on high-growth businesses, investing up to £5 million in any particular company. 24Haymarket’s Investor Network includes several highly experienced private equity and venture capital investors, seasoned entrepreneurs and senior operators. We invest our own capital in direct alignment with entrepreneurs and typically seek Board representation to actively support their growth agenda. Since its inception in 2011, 24Haymarket has invested in more than 50 high-growth businesses.

No events currently scheduled